The DOI matches its Crossref record; 300 of the 302 references it cites were found in a registry or an index.
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Open accessAbstract
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Conversely, myeloid-specific overexpression of HIF-1α results in hyperinflammatory, M1-polarized macrophages associated with increased glycolysis, suggesting a link between HIF-1α and M1-polarization [63].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The possible contribution of the adaptive immune system in AD patients to reducing cancer incidence has not been studied (4,5).”
From Alzheimer's Disease–Associated Amyloid-β Precursor Protein Prevents Aging Stress–Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Typically, PD‐L1 or PD‐L2 are expressed on the surface of cancer cells or antigen‐presenting cells and transduce a signal for cooperation with PD‐1 expression on the cell surface of T lymphocytes to stimulate restraint signaling [272, 273].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Cited by
Sorted by citations
Items 901–1,000 of 1,006
Rolig, A. S., Rose, D. C., McGee, G. H., Rubas, W., Kivimäe, S., & Redmond, W. L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004218 · Cited by 31
HP-NAP of Helicobacter pylori: The Power of the Immunomodulation
Codolo, G., Coletta, S., D’Elios, M. M., & de Bernard, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944139 · Cited by 31
Yazgan, S. C., Yekedüz, E., Utkan, G., & Ürün, Y. (2022) · The Prostate · doi:10.1002/pros.24419 · Cited by 32
Franson, A. T., McClellan, B. L., Varela, M. L., Comba, A., Syed, M. F., Banerjee, K., Zhu, Z., González, N., Candolfi, M., Lowenstein, P. R., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.966458 · Cited by 31
SpyPhage: A Cell-Free TXTL Platform for Rapid Engineering of Targeted Phage Therapies
Liyanagedera, S. B. W., Williams, J., Wheatley, J. P., Biketova, A. Y., Hasan, M., Sagona, A. P., Purdy, K. J., Puxty, R. J., Fehér, T., & Kulkarni, V. V. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00244 · Cited by 31
Aptamers in cancer therapy: problems and new breakthroughs
Jin, B., Guo, Z., Chen, Z., Chen, H., Li, S., Deng, Y., Jin, L. J., Liu, Y., Zhang, Y., & He, N. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02579e · Cited by 33
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment
Singh, S., Barik, D., Arukha, A. P., Prasad, S., Mohapatra, I., Singh, A. R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11102621 · Cited by 31
[Pharmacokinetics and metabolism of trazodone in man (author's transl)].
Jauch, R., Kopitar, Z., Prox, A., & Zimmer, A. (1976) · PubMed · Cited by 31
The effect of organ-specific tumor microenvironments on response patterns to immunotherapy
Conway, J. W., Braden, J., Wilmott, J. S., Scolyer, R. A., Long, G. V., & da Silva, I. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030147 · Cited by 32
T Cell Development and Function
Adu‐Berchie, K., Obuseh, F. O., & Mooney, D. J. (2023) · Rejuvenation Research · doi:10.1089/rej.2023.0015 · Cited by 34
Minarti, I. B., Dzakiy, M. A., & Nilautama, D. (2023) · At-Tasyrih jurnal pendidikan dan hukum Islam · doi:10.55849/attasyrih.v8i2.151 · Cited by 46
Qin, Y., Wang, G., Chen, L., Sun, Y., Yang, J., Piao, Y., Shen, Y., & Zhou, Z. (2023) · Advanced Materials · doi:10.1002/adma.202302292 · Cited by 31
Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer
Mori, J., Elhussin, I. A., Brennen, W. N., Graham, M. K., Lotan, T. L., Yates, C. C., Marzo, A. M. D., Denmeade, S. R., Yegnasubramanian, S., Nelson, W. G., et al. (2023) · Nature Reviews Urology · doi:10.1038/s41585-023-00827-x · Cited by 32
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou, I., Kalafateli, M., & Triantos, C. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052631 · Cited by 31
Raybould, M. I. J., Greenshields‐Watson, A., Agarwal, P., Aguilar-Sanjuan, B., Olsen, T. H., Turnbull, O. M., Quast, N. P., & Deane, C. M. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114704 · Cited by 30
Franzese, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312848 · Cited by 29
Immunoregulatory mechanisms of the arachidonic acid pathway in cancer
Tredicine, M., Mucci, M., Recchiuti, A., & Mattoscio, D. (2025) · FEBS Letters · doi:10.1002/1873-3468.70013 · Cited by 33
Zhao, Y., Yu, J., Su, Y., Shu, Y., Ma, E., Wang, J., Jiang, S., Wei, C., Li, D., Huang, Z., et al. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-025-01002-0 · Cited by 32
Wen, N., Lu, Y., Zhuo, Y., Fu, B., Wang, H., He, Y., Wu, H., Wang, Z., Tan, W., & Qiu, L. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18455 · Cited by 30
Engineering Living Bacteria for Cancer Therapy
Rong, L., Lei, Q., & Zhang, X. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01286 · Cited by 30
Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison
de Miguel, D., Ramírez-Labrada, A., Uranga-Murillo, I., Hidalgo, S., Santiago, L., Gálvez, E. M., Arias, M. A., & Pardo, J. (2021) · FEBS Journal · doi:10.1111/febs.16093 · Cited by 33
Wang, L., Zhang, D., Li, J., Li, F., Wei, R., Jiang, G., Xu, H., Wang, X., Zhou, Y., & Xi, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113935 · Cited by 30
Visualizing T-Cell Responses: The T-Cell PET Imaging Toolbox
Li, C., Han, C., Duan, S., Li, P., Alam, I. S., & Xiao, Z. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261976 · Cited by 31
Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
Comito, F., Pagani, R., Grilli, G., Sperandi, F., Ardizzoni, A., & Melotti, B. (2022) · Cancers · doi:10.3390/cancers14020271 · Cited by 32
Barth, D. A., Stanzer, S., Terzic, J. A., Bauernhofer, T., Absenger, G., Szkandera, J., Gerger, A., Smolle, M. A., Hutterer, G. C., Ahyai, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840207 · Cited by 30
Baek, H.-S., Jeong, C., Shin, K., Lee, J., Suh, H., Lim, D., Kang, M. I., & Ha, J. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01004-8 · Cited by 30
Exploring chitosan-shelled nanobubbles to improve HER2 + immunotherapy via dendritic cell targeting
Argenziano, M., Occhipinti, S., Scomparin, A., Angelini, C., Novelli, F., Soster, M., Giovarelli, M., & Cavalli, R. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01185-8 · Cited by 31
Cationic lipid potentiated the adjuvanticity of polysaccharide derivative-modified liposome vaccines
Yuba, E., Kado, Y., Kasho, N., & Harada, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.016 · Cited by 32
Designing polymers with stimuli-responsive degradation for biomedical applications
Li, C., Deng, Z., & Gillies, E. R. (2022) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2022.100437 · Cited by 30
Sun, J., Zhang, H., Wei, W., Xiao, X., Huang, C., Wang, L., Zhong, H., Jiang, Y., Zheng, F., Yang, H., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02637-2 · Cited by 31
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
Whalen, K. A., Rakhra, K., Mehta, N. K., Steinle, A., Michaelson, J. S., & Baeuerle, P. A. (2023) · mAbs · doi:10.1080/19420862.2023.2208697 · Cited by 33
Liang, Y., Wang, B., Chen, Q., Fu, X., Jiang, C., Lin, Z., Zhuang, Q., Zeng, Y., Liu, X., & Zhang, D. (2023) · Theranostics · doi:10.7150/thno.87498 · Cited by 29
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Fuchs, N. S., Zhang, L., Calvo‐Barreiro, L., Kuncewicz, K., & Gabr, M. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010068 · Cited by 29
Gao, N., Huang, Y., Jing, S., Zhang, M., Liu, E., Qiu, L., Huang, J., Muhitdinov, B. I., & Huang, Y. (2024) · Theranostics · doi:10.7150/thno.94354 · Cited by 29
Liang, J., Jin, X., Deng, X., Huang, Q., Zhang, S., Chen, W., & Zhang, X. (2024) · Materials Today · doi:10.1016/j.mattod.2024.07.004 · Cited by 30
Recent Advances and Prospects of Nucleic Acid Therapeutics for Anti-Cancer Therapy
Lee, M., Lee, M.-J., Song, Y., Kim, S., & Park, N. (2024) · Molecules · doi:10.3390/molecules29194737 · Cited by 31
In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy
Qu, J., Wang, Y., Xiong, C., Wang, M., He, X., Jia, W., Li, C. Y., Zhang, T., Wang, Z., Li, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54292-0 · Cited by 31
Cacciottola, L., Camboni, A., & Dolmans, M. (2024) · Human Reproduction · doi:10.1093/humrep/deae254 · Cited by 30
Vaccines for cancer prevention: exploring opportunities and navigating challenges
Graciotti, M., & Kandalaft, L. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01081-5 · Cited by 30
Ahuja, S., & Zaheer, S. (2024) · Korean Journal of Clinical Oncology · doi:10.14216/kjco.24009 · Cited by 31
LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment
Xue, Y., Hou, X., Zhong, Y., Zhang, Y., Du, S., Kang, D. D., Wang, L., Wang, C., Li, H., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57149-2 · Cited by 30
Ebrahim, N. A. A., Soliman, S. M. A., Othman, M. O., & Tahoun, N. S. (2025) · Medical Oncology · doi:10.1007/s12032-025-02729-x · Cited by 31
Arecco, L., Leite, L. D. M., Gentile, G., Janković, K., Stana, M., Ottonello, S., Scavone, G., Spinaci, S., & Lambertini, M. (2025) · Human Reproduction · doi:10.1093/humrep/deaf096 · Cited by 33
Advances in Targeting Cutaneous Melanoma
Kasakovski, D., Skrygan, M., Gambichler, T., & Susok, L. (2021) · Cancers · doi:10.3390/cancers13092090 · Cited by 29
Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review)
Vivarelli, S., Falzone, L., Leonardi, G. C., Salmeri, M., & Libra, M. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5255 · Cited by 29
Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential
Ryder, C. B., Kondolf, H. C., O'Keefe, M. E., Zhou, B., & Abbott, D. W. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167183 · Cited by 28
Localized delivery of immunotherapeutics: A rising trend in the field
Wang, J., Zhang, Y., Pi, J., Xing, D., & Wang, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.013 · Cited by 31
Rising Interest in the Development of Metal Complexes in Cancer Immunotherapy
Li, Z., Shen, Q., Mao, Z., & Tan, C. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200270 · Cited by 29
Yang, B., Zhang, Z., Chen, X., Wang, X., Qin, S., Du, L., Yang, C., Zhu, L., Sun, W., Zhu, Y., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 30
Deep neural network modeling identifies biomarkers of response to immune-checkpoint therapy
Kang, Y., Vijay, S., & Gujral, T. S. (2022) · iScience · doi:10.1016/j.isci.2022.104228 · Cited by 30
Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy
Huang, Z. N., Callmann, C. E., Wang, S., Vasher, M. K., Evangelopoulos, M., Petrosko, S. H., & Mirkin, C. A. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00227 · Cited by 31
Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review
Koyande, N. P., Srivastava, R., Padmakumar, A., & Rengan, A. K. (2022) · Vaccines · doi:10.3390/vaccines10101727 · Cited by 32
Zhang, L., Zhang, Q., Hinojosa, D. T., Jiang, K., Pham, Q.-K., Xiao, Z., Colvin, V. L., & Bao, G. (2022) · ACS Nano · doi:10.1021/acsnano.2c06776 · Cited by 31
Yang, Q., Liu, T., Zheng, H., Zhou, Z., Huang, Y., Jia, H., Fu, S., Zhang, X., Zhang, H., Liu, Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121936 · Cited by 29
Improved cancer immunotherapy strategies by nanomedicine
Guo, S., Feng, J., Li, Z., Yang, S., Qiu, X., Xu, Y., & Shen, Z. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1873 · Cited by 29
Immunomodulatory glycomedicine: Introducing next generation cancer glycovaccines
Freitas, R., Peixoto, A., Ferreira, E., Miranda, A., Santos, L. L., & Ferreira, J. A. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108144 · Cited by 29
Advancing cellular immunotherapy with macrophages
Mishra, A., & Malonia, S. K. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121857 · Cited by 29
Afra, F., Mahboobipour, A. A., Farid, A. S., & Ala, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115104 · Cited by 30
Brownlie, D., von Kries, A., Valenzano, G., Wild, N., Yilmaz, E., Säfholm, J., Al‐Ameri, M., Alici, E., Ljunggren, H., Schliemann, I., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2233402 · Cited by 29
Katiyar, V., Chesney, J. A., & Kloecker, G. H. (2023) · Cancers · doi:10.3390/cancers15143733 · Cited by 32
Pérez, A. M. L., Collado‐Mateo, D., Abbasi, S., Ferreira‐Júnior, J. B., & Hekmatikar, A. H. A. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07968-0 · Cited by 31
Zhang, Y., Zhang, R., Liang, F., Zhang, L., & Liang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.598801 · Cited by 32
Cancer immunology and immunotherapy
Ren, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0036 · Cited by 29
Haensel, D., Daniel, B., Gaddam, S., Pan, C., Fabo, T., Bjelajac, J., Jussila, A. R., Gonzalez, F., Li, N. Y., Chen, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37993-w · Cited by 29
Role of T cells in ischemic acute kidney injury and repair
Lee, K., & Jang, H. R. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.526 · Cited by 28
Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy
Pasquarelli-do-Nascimento, G., Machado, S. A., de Carvalho, J. M. A., & Magalhães, K. G. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac015 · Cited by 29
Piggott, L. M., Hayes, C., Greene, J., & Fitzgerald, D. B. (2023) · Breathe · doi:10.1183/20734735.0145-2023 · Cited by 33
Single-cell colocalization analysis using a deep generative model
Kojima, Y., Mii, S., Hayashi, S., Hirose, H., Ishikawa, M., Akiyama, M., Enomoto, A., & Shimamura, T. (2024) · Cell Systems · doi:10.1016/j.cels.2024.01.007 · Cited by 29
PRMT1 acts as a suppressor of MHC-I and anti-tumor immunity
Djajawi, T. M., Pijpers, L., Srivaths, A., Chisanga, D., Chan, K. F., Hogg, S. J., Neil, L., Rivera, S., Bartoniček, N., Ellis, S. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113831 · Cited by 29
Yang, Y. A., Qi, J., Hu, J., Zhou, Y., Zheng, J., Deng, W., Inam, M., Guo, J., Xie, Y., Li, Y., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216765 · Cited by 28
The Tumor Stroma of Squamous Cell Carcinoma: A Complex Environment That Fuels Cancer Progression
Buruiană, A., Gheban, B., Gheban-Roşca, I. A., Georgiu, C., Crișan, D., & Crişan, M. (2024) · Cancers · doi:10.3390/cancers16091727 · Cited by 32
Al-Ostoot, F. H., Salah, S., & Khanum, S. A. (2024) · Cancer Investigation · doi:10.1080/07357907.2024.2361295 · Cited by 30
Tardito, S., Matis, S., Zocchi, M. R., Benelli, R., & Poggi, A. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137131 · Cited by 30
López‐Cortés, A., Cabrera‐Andrade, A., Echeverría‐Garcés, G., Echeverría-Espinoza, P., Pineda-Albán, M., Elsitdie, N., Bueno‐Miño, J., Segundo, C. M. C., Dorado, J., Pazos, A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68565-7 · Cited by 28
Nanozymes in cancer immunotherapy: metabolic disruption and therapeutic synergy
Xu, X., Zhang, Y., Meng, C., Zheng, W., Wang, L., Zhao, C., & Luo, F. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00769g · Cited by 28
DNA Nanostructures: Advancing Cancer Immunotherapy
Chen, Q., Liu, Y., Chen, Q., Li, M., Xu, L., Lin, B., Tan, Y., & Liu, Z. (2024) · Small · doi:10.1002/smll.202405231 · Cited by 27
Gastroenteropancreatic neuroendocrine neoplasms: epidemiology, genetics, and treatment
Tan, B., Zhang, B., & Chen, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1424839 · Cited by 31
Sukumaran, R. A., Lakavath, K., Phanikumar, V. V. N., Karingula, S., Mahato, K., & Goud, K. Y. (2024) · Nanoscale · doi:10.1039/d4nr04010d · Cited by 29
Tao, J., Dong, Y., Wang, B., Wang, T., Zhang, A., Li, S., Chen, R., Su, Y., Jiang, T., & Zhao, X. (2025) · Small · doi:10.1002/smll.202409187 · Cited by 29
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 29
Interplay between cancer-associated fibroblasts and dendritic cells: implications for tumor immunity
Mentucci, F. M., Ferrara, M. G., Ercole, A., Vittar, N. B. R., & Lamberti, M. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1515390 · Cited by 29
Grabowska, J. A., Stolk, D. A., Twilhaar, M. K. N., Ambrosini, M., Storm, G., van der Vliet, H. J., de Gruijl, T. D., van Kooyk, Y., & den Haan, J. M. M. (2021) · Vaccines · doi:10.3390/vaccines9010056 · Cited by 29
Yoon, S. J., Lee, C. B., Chae, S. U., Jo, S. J., & Bae, S. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136932 · Cited by 27
Whole-body PET Imaging of T-cell Response to Glioblastoma
Nobashi, T. W., Mayer, A. T., Xiao, Z., Chan, C. T., Chaney, A. M., James, M. L., & Gambhir, S. S. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1412 · Cited by 28
Izadi, M., Ali, T. A., & Pourkarimi, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212466 · Cited by 30
Complications following novel therapies for non‐small cell lung cancer
Skribek, M., Rounis, K., Tsakonas, G., & Ekman, S. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13445 · Cited by 28
Merali, N., Chouari, T. A. M., Kayani, K., Rayner, C. J., Jiménez, J. I., Krell, J., Giovannetti, E., Bagwan, I., Relph, K., Rockall, T., et al. (2022) · Cancers · doi:10.3390/cancers14041020 · Cited by 29
Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 29
Oyer, J. L., Croom-Perez, T. J., Dieffenthaller, T. A., Robles-Carillo, L. D., Gitto, S. B., Altomare, D. A., & Copik, A. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.861681 · Cited by 28
Noori, S., Nourbakhsh, M., Imani, H., Deravi, N., Salehi, N., & Abdolvahabi, Z. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03625-x · Cited by 28
Yamaguchi, K., Minashi, K., Sakai, D., Nishina, T., Omuro, Y., Tsuda, M., Iwagami, S., Kawakami, H., Esaki, T., Sugimoto, N., et al. (2022) · Cancer Science · doi:10.1111/cas.15462 · Cited by 28
Guo, M., Vanderwalde, A. M., Yu, X., Vidal, G. A., & Tian, G. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.015 · Cited by 31
A synthetic DNA template for fast manufacturing of versatile single epitope mRNA
de Mey, W., Schrijver, P. D., Autaers, D., Pfitzer, L., Fant, B., Locy, H., Esprit, A., Lybaert, L., Bogaert, C., Verdonck, M., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.021 · Cited by 28
Pre-clinical models for evaluating glioma targeted immunotherapies
Frederico, S. C., Zhang, X., Hu, B., & Kohanbash, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1092399 · Cited by 27
Nakamura, S., Ohuchida, K., Ohtsubo, Y., Yamada, Y., Tsutsumi, C., Okuda, S., Hisano, K., Mochida, Y., Shinkawa, T., Iwamoto, C., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1181 · Cited by 27
Clinical advances in epigenetic therapies for lymphoma
Rosenthal, A. C., Munoz, J. L., & Villasboas, J. C. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01452-6 · Cited by 29
Zhang, R., Li, R., Zhang, L., Chen, G., Mo, L., Jiang, R., Xu, X., Wang, X., Zhao, Y., Zhang, L., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c01743 · Cited by 28
Metal-Based Nanoparticles for Cancer Metalloimmunotherapy
Suliman, I. H., Kim, K. H., Chen, W., Kim, Y., Moon, J. H., Son, S., & Nam, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15072003 · Cited by 28
Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy
Xiang, J., Liu, K., Xu, H., Zhao, Z., Piao, Y., Shao, S., Tang, J., Shen, Y., & Zhou, Z. (2023) · Advanced Science · doi:10.1002/advs.202301216 · Cited by 27
Aghlara-Fotovat, S., Nash, A., Kim, B., Krencik, R., & Omid Veiseh, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01018-0 · Cited by 29
Metadata
- Authors
- Waldman, A. D., Fritz, J. M., & Lenardo, M. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lenardo, Michael J.
- Venue
- Nature Reviews Immunology
- Published
- 2020-05-20
- Volume
- 20
- Issue
- 11
- Pages
- 651-668
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7238960
- OpenAlex
- W3028523516
- Cited by
- 4,154
- References
- 302
- Citations by year
- 2026: 382 · 2025: 748 · 2024: 867 · 2023: 824 · 2022: 754 · 2021: 511 · 2020: 59
- FWCI
- 58.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Emory University
- National Institutes of Health
- National Institute of General Medical Sciences (T32GM008169)
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, T cells, T cell regulation, immune checkpoint blockade, adoptive cellular therapy, clinical trials, immunotherapy toxicity, history of cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
